Abstract:Background: Currently, no satisfactory biomarkers are available to screen for lung cancer. Surface-Enhanced Laser Desorption/ionization Time-of- Flight Mass Spectrometry ProteinChip system (SELDI-TOF-MS) is one of the currently used techniques to identify biomarkers for cancers. The aim of this study is to explore the application of serum SELDI proteomic patterns to distinguish lung cancer patients from healthy individuals.Methods: A total of 208 serum samples, including 158 lung cancer patients and 50 healthy individuals, were randomly divided into a training set (including 11 sera from patients with stages I/II lung cancer, 63 from patients with stages III/IV lung cancer and 20 from healthy controls) and a blinded test set (including 43 sera from patients with stages I/II lung cancer, 41 from patients with stages III/IV lung cancer and 30 from healthy controls). All samples were analyzed by SELDI technology. The spectra were generated on weak cation exchange (WCX2) chips, and protein peaks clustering and classification analyses were made using Ciphergen Biomarker Wizard and Biomarker Pattern software, respectively. We additionally determined Cyfra21-1 and NSE in the 208 serum samples included in this study using an electrochemiluminescent immunoassay.Results: Five protein peaks at 11493, 6429, 8245, 5335 and 2538 Da were automatically chosen as a biomarker pattern in the training set. When the SELDI marker pattern was tested with the blinded test set, it yielded a sensitivity of 86.9%, a specificity of 80.0% and a positive predictive value of 92.4%. The sensitivities provided by Cyfra21-1 and NSE used individually or in combination were significantly lower than that of the SELDI marker pattern (P < 0.005 or 0.05, respectively). Based on the results of the test set, we found that the SELDI marker pattern showed a sensitivity of 91.4% in the detection of non-small cell lung cancers (NSCLC), which was significantly higher than that in the detection of small cell lung cancers (P < 0.05); The pattern also had a sensitivity of 79.1% in the detection of lung cancers in stages I/II.Conclusion: These results suggest that serum SELDI protein profiling can distinguish lung cancer patients, especially NSCLC patients, from normal subjects with relatively high sensitivity and specificity, and the SELDI- TOF- MS is a potential tool for the screening of lung cancer.

Serum Protein Fingerprinting Coupled with Artificial Neural Network Distinguishes Glioma from Healthy Population or Brain Benign Tumor

Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population and brain benign tumo

[Application of Saliva Protein Fingerprints in the Diagnosis of Oral Squamous Cell Cancer by Surface Enhanced Laser Desorption Ionization Time of Flight Mass].

Establishment of Diagnostic Model of Cerebrospinal Protein Fingerprint Pattern for Glioma and Its Clinical Application

Mass Spectrometric Analysis of Cerebrospinal Fluid Protein for Glioma and Its Clinical Application

Fingerprint pattern analysis of glioma CSF protein with mass spectrometry and its clinical significance

[Use of Laser Capture Microdissection and Surface-Enhanced Laser Desorption Ionization Time-of-flight Mass Spectrometry to Screen Differential Proteins in Lung Adenocarcinoma and Lung Squamous Carcinoma].

Discovery of Serum Biomarkers in Astrocytoma by SELDI–TOF MS and Proteinchip Technology

Application of Serum Surface-Enhanced Laser Desorption/ionization Proteomic Patterns in Distinguishing Lung Cancer Patients from Healthy People.

Artificial Neural Networks Analysis Of Surface-Enhanced Laser Desorption/Ionization Mass Spectra Of Serum Protein Pattern Distinguishes Colorectal Cancer From Healthy Population

Application of Serum Seldi Proteomic Patterns in Diagnosis of Lung Cancer

SELDI-TOF Analysis of Cerebrospinal Protein Profiling to Build the Peptide Patterns for Distinguishing Meningiomas from Brain Traumas and Other Benign Brain Tumors

Diagnosis of pancreatic adenocarcinoma using protein chip technology.

Screening Glioma’s Disease-Related Proteins in Serum

Application of Seldi-Tof-Ms Coupled with an Artificial Neural Network Model to the Diagnosis of Pancreatic Cancer

Proteomic Analysis of Cerebrospinal Fluid: Toward the Identification of Biomarkers for Gliomas.

[Application of SELDI-TOF MS Technology Analyzing Serum Protein Profiling for Distinguishing Laryngeal Carcinoma from Ordinary People].

Label-free discrimination of glioma brain tumors in different stages by surface enhanced Raman scattering

Human serum mid-infrared spectroscopy combined with machine learning algorithms for rapid detection of gliomas

Study of Distinct Protein Profiles for Early Diagnosis of NSCLC Using LCM and SELDI-TOF-MS

Urinary biomarker discovery in gliomas using mass spectrometry-based clinical proteomics